Clinical trial addresses HIV and cardiovascular risks

Researchers at two area universities are among those participating in a nationwide clinical trial focused on HIV-related cardiovascular disease.

University of Illinois at Chicago and Northwestern University are two local sites of the six-year clinical trial, known as the Randomized Trial to Prevent Vascular Events in HIV ( REPRIEVE ). About 6,500 subjects across the country are expected to participate in the study, which hypothesizes that statins should reduce plaque development and improve cardiovascular outcomes in patients with HIV.

Matt Simonette
Windy City Times

Read the full article here.